Role of oxycodone and oxycodone/naloxone in cancer pain management.
Journal Title: Pharmacological Reports - Year 2010, Vol 62, Issue 4
Abstract
Oxycodone is a valued opioid analgesic, which may be administered either as the first strong opioid or when other strong opioids are ineffective. In case of insufficient analgesia and/or intense adverse effects such as sedation, hallucinations and nausea/vomiting a switch from another opioid to oxycodone might be beneficial. Oxycodone is administered to opioid-naive patients with severe pain and to patients who were unsuccessfully treated with weak opioids, namely tramadol, codeine and dihydrocodeine. Oxycodone effective analgesia may be attributed to its affinity to μ and possibly κ opioid receptors, rapid penetration through the blood-brain barrier and higher concentrations in brain than in plasma. Oxycodone displays high bioavailability after oral administration and may be better than morphine in patients with renal impairment due to the decreased production of active metabolites. Recently an oral controlled-release oxycodone formulation was introduced in Poland. Another new product that was launched recently is a combination of prolonged-release oxycodone with prolonged-release naloxone (oxycodone/naloxone tablets). The aim of this review is to outline the pharmacodynamic and pharmacokinetic properties, drug interactions, dosing rules, adverse effects, equianalgesic dose ratio with other opioids and clinical studies of oxycodone in patients with cancer pain. The potential role of oxycodone/naloxone in chronic pain management and its impact on the bowel function is also discussed.
Authors and Affiliations
Wojciech Leppert
Keywords
Related Articles
- EP ID EP118911
- DOI -
- Views 98
- Downloads 0
Simvastatin inhibits the increase in serum tau protein levels in the acute phase of ischemic stroke.
Our goal was to analyze the effects of treatment with a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (simvastatin, 40 mg/day) on serum S100BB and tau protein levels during the acute ischemic stroke...
Effect of classic and atypical neuroleptics on cytochrome P450 3A (CYP3A) in rat liver.
BACKGROUNd: Cytochrome P450 3A (CYP3A) subfamily is involved in the metabolism of xenobiotics (e.g., drugs) and endogenous substances (e.g., steroids). The aim of the present study was to investigate the influence of cla...
Effect of thymoquinone on the lung pathology and cytokine levels of ovalbumin-sensitized guinea pigs.
Different pharmacological effects from Nigella sativa have been demonstrated in guinea pig tracheal chains in previous studies. In the present study, the prophylactic effects of thymoquinone on lung pathology as well as...
Zinc deficiency alters responsiveness to antidepressant drugs in mice.
Background: There is some evidence coming from preclinical and clinical studies suggesting a relationship between dietary zinc intake and depressive symptoms. The aim of the study was to determine whether zinc deficiency...
Study of the protective effect of calcium channel blockers against neuronal damage induced by glutamate in cultured hippocampal neurons.
Background: The aim of this study was to examine the putative protective effect of calcium channel blockers on hippocampal neurons in the experimental model of excitotoxic damage. Methods: Seven-day old primary dissociat...